Dr. Matthew Might

Dr. Matthew Might has been the Director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham (UAB) since 2017. At UAB, Dr. Might is the Hugh Kaul Endowed Chair of Personalized Medicine, a Professor of Internal Medicine and a Professor of Computer Science. At UAB, Dr. Might's research focuses on precision prevention, diagnosis and therapeutics using genomics, model systems, drug screens and artificial intelligence. A principal theme in his research is the use of computer and data science to enhance clinical and academic medicine.
 

From 2016 to 2018, Dr. Might was a Strategist in the Executive Office of the President in The White House. At The White House, Dr. Might worked primarily on President Obama's Precision Medicine Initiative with both the NIH and the Department of Veterans Affairs. In 2015, Dr. Might joined the faculty of the Department of Biomedical Informatics at the Harvard Medical School, first as Visiting Professor and since 2017 as Senior Lecturer. At Harvard, Dr. Might's research focuses on rare disease discovery and diagnosis, and on the development of personalized therapeutics.

Dr. Might is co-founder and Chief Scientific Officer of NGLY1.org, a non-profit dedicated to finding treatments for NGLY1 deficiency, and he was a co-founder and Scientific Advisor to Pairnomix, a start-up which identifies potential patient-specific therapies for rare disorders -- and genetic epilepsies in particular. Q State Biosciences acquired Pairnomix in October 2018 and Dr. Might remains a Scientific Advisor and Board Member.

 

Dr. Might received his B.S. (2001), M.S. (2005) and Ph.D. (2007) in computer science from Georgia Tech.